鸡参芪抗癌颗粒的制备工艺和质量标准研究

Study on the preparation process and quality standard of Ji Shenqi anti-cancer granules

  • 摘要:
    目的 初步筛选鸡参芪抗癌颗粒的制备工艺,并建立质量标准。
    方法 以制软材情况、颗粒收率、休止角及溶化性为评价指标,对赋形剂种类进行考察,优选制剂成型工艺。采用薄层色谱(TLC)法对鸡血藤、人参、黄芪进行定性鉴别;采用高效液相色谱(HPLC)法测定制剂中人参皂苷(Rg1、Re和Rb1)和儿茶素的质量分数。
    结果 辅料为可溶性淀粉、甘露醇, 最佳制备工艺为主药与可溶性淀粉和甘露醇比例1∶1.5∶0.3。结合课题组前期提取工艺研究结果,鸡参芪抗癌颗粒的制备工艺为:处方量药材第1次加水量9倍浸泡80 min,其余两次均加水8倍量,每次煎煮1 h,共提取3次,过滤并合并滤液,减压浓缩至相对密度在1.20~1.30,稠膏与辅料(可溶性淀粉∶甘露醇=1.5∶0.3)按照药辅比为1∶1.8的比例混合均匀制软材,制粒,干燥,整粒,即得。TLC斑点清晰、分离良好,阴性无干扰,专属性强;质量检查符合药典规定;结果表明人参皂苷(Rg1、Re和Rb1)和儿茶素质量浓度的线性范围分别为6.96~139.20 μg/mL,7.51~150.20 μg/mL,7.35~147.00 μg/mL和5.86~187.52 μg/mL范围内(r值均>0.99),与峰面积呈良好的线性关系;平均加样回收率分别为102.72%、103.81%、99.66%和106.29%,RSD分别为1.18%、2.33%、1.58%和1.64%。测得3批样品中人参皂苷(Rg1、Re和Rb1)和儿茶素平均含量分别为446.14 μg/g、475.91 μg/g、559.71 μg/g和50.40 μg/g, 本品每1 g含儿茶素量≥40.32 μg,含人参皂苷(Rg1、Re、Rb1)≥356.91 μg、380.73 μg、447.77 μg。
    结论 该工艺稳定、可行,建立的TLC和HPLC法专属性强、灵敏度高、重复性好,为后续研发和质量控制奠定了基础。

     

    Abstract:
    Objective To preliminarily screen the preparation process of Ji Shenqi anti-cancer granules (JSQ) and establish the quality standard.
    Methods The excipient types were examined and the formulation moulding process was preferred using the soft material making situation, particle yield, angle of repose and solubility as evaluation indexes. Thin-layer chromatography (TLC) was used for the qualitative identification of Suberect Spatholobus Stem, ginseng, and astragalus; high performance liquid chromatography (HPLC) was used to determine the mass fractions of ginsenosides (Rg1, Re, and Rb1) and catechins in the preparations.
    Results The excipients were soluble starch and mannitol, and the best preparation process was that the ratio of main drug to soluble starch and mannitol was 1∶1.5∶0.3. Combined with the previous research results of the extraction process by the research group, the preparation process of JSQ was as follows: The prescription amount of herbs with 9 times the amount of water was soaked for 80 min for the first time, and the remaining two times were added with 8 times the amount of water; each time was decocted for 1 h; after a total of three extractions, the filtrates were filtered and combined, and then concentrated under reduced pressure to achieve the relative density in the range of 1.20-1.30; the thick paste was then mixed with excipients (soluble starch: mannitol=1.5∶0.3) in accordance with the ratio of drugs and auxiliaries for 1∶1.8. The mixture was evenly combined to make a soft material, which was then granulated, dried, and granulated again to obtain the final product. The TLC spots were clear, well-separated, negative and non-interfering, with strong specificity; the quality check was in accordance with the provisions of the Pharmacopoeia; the results showed that the linear ranges of the mass concentrations of ginsenosides (Rg1, Re and Rb1) and catechins were 6.96-139.20 μg/mL, 7.51-150.20 μg/mL, 7.35-147.00 μg/mL and 5.86-187.52 μg/ mL, respectively (all r > 0.99), with good linear relationship with the peak area; the average recoveries were 102.72%, 103.81%, 99.66% and 106.29%, with RSDs of 1.18%, 2.33%, 1.58% and 1.64%, respectively. The average contents of ginsenosides and catechins in the three batches of samples were 446.14 μg/g, 475.91 μg/g, 559.71 μg/g and 50.40 μg/g, respectively, and the amount of catechins in this product was not less than 40.32 μg per 1 g, and the amount of ginsenosides (Rg1, Re, and Rb1) was not less than 356.91 μg, 380.73 μg and 447.77 μg.
    Conclusion The process is stable and feasible, and the established TLC and HPLC methods are exclusive, sensitive and reproducible, laying a foundation for the subsequent research and development and quality control.

     

/

返回文章
返回